Update on the ARQ 197 Clinical Trial (November 23):
The new clinical trial (read below) is now open and at least two ASPS patients are already participating in it.
If you are interested to join the trial please read the information below and contact Dr. Isett Laux, the study coordinator for this study.
Tel: 310-633 8400, 310-633 8419
From the site of “Premiere Oncology”:
“A Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transciption Factor Assciated Tumors.
The purpose of this study is to determine the overall response rate in patients with unresectable locally advanced or metastatic alveolar soft parts sarcoma, clear cell sarcoma or translocation associated renal cell carcinoma. Since this study will allow patients over 13 years of age, it will also be evaluating the safety of ARQ 197 in adolescent and young adult patients with MiT tumors. Patients will be followed for the effect of the drug in terms of side effects, how it affects their disease, and pharmacokinetic testing. Pharmacokinetics (PKs) is a method to determine the levels of a drug in the blood and see how the body absorbs, distributes, metabolizes and eliminates it. This is done by frequent blood draws on key days during the first 4 weeks of treatment.
ARQ 197 is an oral drug in the family of targeted therapies. It is a c-Met inhibitor and is not approved by the FDA. In this study, it is an investigational drug.”
For direct link to “Premiere Oncology” website please click here.
Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)